IP Verse

Combination Therapy Using Inhibitors Of Human Growth And Differentiation Factor 15 (Gdf-15) And Immune Checkpoint Blockers - EP3355919

The patent EP3355919 was granted to Julius Maximilians Universitt Wrzburg on Dec 7, 2022. The application was originally filed on Sep 30, 2016 under application number EP16778750A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3355919

JULIUS MAXIMILIANS UNIVERSITT WRZBURG
Application Number
EP16778750A
Filing Date
Sep 30, 2016
Status
Granted And Under Opposition
Nov 4, 2022
Grant Date
Dec 7, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PFIZERSep 6, 2023PFIZERADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2015EP56654-
DESCRIPTIONWO2005099746
DESCRIPTIONWO2009021293
DESCRIPTIONWO2014049087
DESCRIPTIONWO2014100689
INTERNATIONAL-SEARCH-REPORTWO2015144855
OPPOSITIONUS2020055930
OPPOSITIONWO2014049087
OPPOSITIONWO2015144855

Non-Patent Literature (NPL) Citations (44) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- LINDA YANG ET AL, "Gfral is the receptor for GDF15 and is required for the anti-obesity effects of the ligand (includes Online methods and supplementary information)", NATURE MED ADVANCE ONLINE PUBLICATION, (20170828), pages 1 - 9+12PP, XP055427403-
EXAMINATION- Sine Hadrup ET AL, "Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment", CANCER MICROENVIRONMENT, NL, (20121216), vol. 6, no. 2, doi:10.1007/s12307-012-0127-6, ISSN 1875-2292, pages 123 - 133, XP055712388
EXAMINATION- JERBY-ARNON LIVNAT ET AL, "A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade", CELL, ELSEVIER, AMSTERDAM, NL, (20181101), vol. 175, no. 4, doi:10.1016/J.CELL.2018.09.006, ISSN 0092-8674, page 984, XP085522248
EXAMINATION- DANIEL�S. CHEN ET AL, "Oncology Meets Immunology: The Cancer-Immunity Cycle", IMMUNITY, AMSTERDAM, NL, (20130701), vol. 39, no. 1, doi:10.1016/j.immuni.2013.07.012, ISSN 1074-7613, pages 1 - 10, XP055593768
EXAMINATION- GEORGINA V LONG ET AL, "Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study", THE LANCET ONCOLOGY, AMSTERDAM, NL, (20190801), vol. 20, no. 8, doi:10.1016/S1470-2045(19)30274-8, ISSN 1470-2045, pages 1083 - 1097, XP55712377
EXAMINATION- Ping Yu ET AL, "Tumor-infiltrating T lymphocytes: friends or foes?", Laboratory Investigation, The United States and Canadian Academy of Pathology, Inc., (20060130), vol. 86, no. 3, doi:10.1038/labinvest.3700389, ISSN 0023-6837, pages 231 - 245, XP55712391
EXAMINATION- PAUL C. TUMEH ET AL, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", NATURE, London, (20141127), vol. 515, no. 7528, doi:10.1038/nature13954, ISSN 0028-0836, pages 568 - 571, XP055247294
EXAMINATION- DANIEL S. CHEN ET AL, "Elements of cancer immunity and the cancer?immune set point", NATURE, London, (20170101), vol. 541, no. 7637, doi:10.1038/nature21349, ISSN 0028-0836, pages 321 - 330, XP055674543
EXAMINATION- Jer-Yuan Hsu ET AL, "Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15 (Includes methods)", Nature, doi:10.1038/nature24042, (20170101), pages 1 - 5+18PP, URL: http://www.nature.com/articles/nature24042.pdf, (20171122), XP055427571
EXAMINATION- STEFANI SPRANGER ET AL, "Tumor-intrinsic oncogene pathways mediating immune avoidance", ONCOIMMUNOLOGY, (20150831), vol. 5, no. 3, doi:10.1080/2162402X.2015.1086862, page e1086862, XP055712371
EXAMINATION- Kevin B. Walsh ET AL, "NKG2D Receptor Signaling Enhances Cytolytic Activity by Virus-Specific CD8+ T Cells: Evidence for a Protective Role in Virus-Induced Encephalitis", Journal of Virology, US, (20071226), vol. 82, no. 6, doi:10.1128/JVI.02033-07, ISSN 0022-538X, pages 3031 - 3044, XP55712385
EXAMINATION- HAIQING PENG ET AL, "Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma", CANCER MANAGEMENT AND RESEARCH, (20190401), Volume 11, doi:10.2147/CMAR.S192095, pages 2653 - 2661, XP055712392
EXAMINATION- Kerima Maasho ET AL, "Cutting Edge: NKG2D Is a Costimulatory Receptor for Human Naive CD8 + T Cells", The Journal of Immunology, US, (20050415), vol. 174, no. 8, doi:10.4049/jimmunol.174.8.4480, ISSN 0022-1767, pages 4480 - 4484, XP55712379
OPPOSITION- Anonymous, "A Study of Galunisertib (LV2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma ", Clinical Trials NCT02423343, (20210909), pages 1 - 18, XP093246021-
OPPOSITION- Anonymous, "Galunisertib - Wikipedia", Wikipedia, (20231203), pages 1 - 2, Wikipedia, URL: https://en.wikipedia.org/wiki/Galunisertib, XP093157999-
OPPOSITION- D41 - additional information outlining the general pre-print publication practice of “Research Square” (https://www.researchsquare.com/researchers/preprints-
OPPOSITION- Jer Yuan Hsu, "Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15", Nature, (20171012), vol. 550, pages 255 - 278, XP093157994-
OPPOSITION- Linda Yang, Chih-Chuan Chang, Zhe Sun, Dennis Madsen, Haisun Zhu, Soren B Padkjrer, Xiaoai Wu, Tao Huang, Karin Hultman, Sarah J Paulsen, Jishu Wang, Anne Bugge, Jane Boesen Frantzen, Per Norgaard, Jacob Fuglsbjerg Jeppesen, Zhiru Yang, Anna Secher, Haibin Chen, Xun Li, Linu Mary John, Bing Shan, Zhenhua He, Xiang Gao, Jing Su, Kristian T Hansen, Wei Yang & Sebastian Beck Jorgensen, "Gfral is the receptor for GDF15 and is required for the anti-obesity effects of the ligand (includes Online methods and supplementary information)", Nature Med Advance Online Publication, pages 1 - 9+12PP, XP055427403-
OPPOSITION- Rosemary L Kanasty, "Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles ", The American Society of Gene & Cell Therapy, (20120303), vol. 20, no. 3, pages 513 - 524, XP093157971-
OPPOSITION- Stephan Herbertz et al., "Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway", Drug Design, Development and Therapy , (2015), vol. 9, XP002765096-
OPPOSITION- Núria Morral, "shRNA-Induced Interferon-Stimulated Gene Analysis", Cytokine Protocols, Totowa, NJ, Humana Press, (20120101), vol. 820, pages 163 - 177, doi:10.1007/978-1-61779-439-1_10, ISSN 1064-3745, ISBN 978-1-61779-439-1, XP093157997
OPPOSITION- Sindhu Annu; Arora Pooja; Chaudhury Ashok, "Illuminating the Gateway of Gene Silencing: Perspective of RNA Interference Technology in Clinical Therapeutics", Molecular Biotechnology, Springer US, New York, New York, (20110925), vol. 51, no. 3, doi:10.1007/s12033-011-9456-9, ISSN 1073-6085, pages 289 - 302, XP037068814
OPPOSITION- Jayashree P. Joshi et al., "Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells ", Biochemical Pharmacology , (2011), vol. 82, doi:10.1016/j.bcp.2011.07.082, XP028326986
OPPOSITION- Suzanne l. Topalian, Charles g. Drake, Drew m. Pardoll, "Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy", CANCER CELL, CELL PRESS, US, US , (20150401), vol. 27, no. 4, doi:10.1016/j.ccell.2015.03.001, ISSN 1535-6108, pages 450 - 461, XP055372181
OPPOSITION- Ammi Rachid; De Waele Jorrit; Willemen Yannick; Van Brussel Ilse; Schrijvers Dorien M.; Lion Eva; Smits Evelien L.J., "Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs", Pharmacology & Therapeutics, ELSEVIER., GB, GB , (19000101), vol. 146, doi:10.1016/j.pharmthera.2014.09.010, ISSN 0163-7258, pages 120 - 131, XP029132937
OPPOSITION- NEUZILLET CINDY ET AL, "Targeting the TGF[beta] pathway for cancer therapy.", PHARMACOLOGY & THERAPEUTICS MAR 2015, (20150301), vol. 147, doi:10.1016/j.pharmthera.2014.11.001, ISSN 1879-016X, pages 22 - 31, XP002765095
OPPOSITION- Georgina V Long, Reinhard Dummer, Omid Hamid, Thomas F Gajewski, Christian Caglevic, Stephane Dalle, Ana Arance, Matteo S Carlino, Jean-Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R Anderson, Janet Maleski, Mark Jones, Scott J Diede, Tara C Mitchell, "Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20190801), vol. 20, no. 8, doi:10.1016/S1470-2045(19)30274-8, pages 1083 - 1097, XP055712377
OPPOSITION- Paul C. Tumeh, Harview Christina L., Yearley Jennifer H., Shintaku I. Peter, Taylor Emma J. M., Robert Lidia, Chmielowski Bartosz, Spasic Marko, Henry Gina, Ciobanu Voicu, West Alisha N., Carmona Manuel, Kivork Christine, Seja Elizabeth, Cherry Grace, Gutierrez Antonio J., Grogan Tristan R., Mateus Christine, Tomasic Gorana, Glaspy John A., Emerson Ryan O., Robins Harlan, Pierce Robert H., Elashoff David A., Robert Caroline, Ribas Antoni, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", Nature, (20141127), vol. 515, no. 7528, doi:10.1038/nature13954, pages 568 - 571, XP055247294
OPPOSITION- Mahesh Yadav et al., "Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing", Nature, (20141127), vol. 515, doi:10.1038/nature14001, XP055514976
OPPOSITION- BRIDGE A J,ET AL, "Induction of an interferon response by RNAi vectors in mammalian cells.", Nature Genetics, Nature Publishing Group US, New York, New York, (20030701), vol. 34, no. 3, doi:10.1038/ng1173, ISSN 1061-4036, pages 263 - 264, XP002251051
OPPOSITION- Wakefield L M, Hill C S, "Beyond TGF.BETA.: roles of other TGF.BETA. superfamily members in cancer", Nature Reviews Cancer, London , (20130501), vol. 13, no. 5, doi:10.1038/nrc3500, ISSN 1474-175X, pages 328 - 341, XP055274527
OPPOSITION- Aimee L. Jackson, Peter S. Linsley, "Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , (20100101), vol. 9, no. 1, doi:10.1038/nrd3010, ISSN 1474-1776, pages 57 - 67, XP055391201
OPPOSITION- Megan Cully, "Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy", Nature Reviews Drug Discovery, (20150601), vol. 14, doi:10.1038/nrd4648, pages 374 - 375, XP055585643
OPPOSITION- Min K-W; Liggett J L; Silva G; Wu W W; Wang R; Shen R-F; Eling T E; Baek S J, "NAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway", Oncogene, Nature Publishing Group UK, London, London , (20150420), vol. 35, no. 3, doi:10.1038/onc.2015.95, ISSN 0950-9232, pages 377 - 388, XP037748377
OPPOSITION- Justine Cohen, Mario Sznol, "Therapeutic Combinations of Immune-Modulating Antibodies in Melanoma and Beyond", SEMINARS IN ONCOLOGY, W.B. SAUNDERS, US, US , (20150601), vol. 42, no. 3, doi:10.1053/j.seminoncol.2015.02.014, ISSN 0093-7754, pages 488 - 494, XP055391644
OPPOSITION- Tosolini Marie, Algans Christelle, Pont Frédéric, Ycart Bernard, Fournié Jean-Jacques, "Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas", OncoImmunology, (20160702), vol. 5, no. 7, doi:10.1080/2162402X.2016.1188246, ISSN 2162-402X, page e1188246, XP093130369
OPPOSITION- Terabe Masaki, Ambrosino Elena, Takaku Shun, O'konek Jessica J., Venzon David, Lonning Scott, Mcpherson John M., Berzofsky Jay A., "Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-β Monoclonal Antibody", Clinical Cancer Research, US, (20091101), vol. 15, no. 21, doi:10.1158/1078-0432.CCR-09-1066, ISSN 1078-0432, pages 6560 - 6569, XP093246009
OPPOSITION- P. Roth, M. Junker, I. Tritschler, M. Mittelbronn, Y. Dombrowski, S. N. Breit, G. Tabatabai, W. Wick, M. Weller, J. Wischhusen, "GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas", Clinical Cancer Research, Association for Cancer Research, (20100801), vol. 16, no. 15, doi:10.1158/1078-0432.CCR-10-0705, ISSN 10780432, pages 3851 - 3859, XP055106395
OPPOSITION- R. H. Vonderheide, M. J. Glennie, "Agonistic CD40 Antibodies and Cancer Therapy", Clinical Cancer Research, Association for Cancer Research, (20130301), vol. 19, no. 5, doi:10.1158/1078-0432.CCR-12-2064, ISSN 10780432, pages 1035 - 1043, XP055218372
OPPOSITION- David J. Messenheimer, Shawn M. Jensen, Michael E. Afentoulis, Keith W. Wegmann, Zipei Feng, David J. Friedman, Michael J. Gough, Walter J. Urba, Bernard A. Fox, "Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40", Clinical Cancer Research, US, (20171015), vol. 23, no. 20, doi:10.1158/1078-0432.CCR-16-2677, ISSN 1078-0432, pages 6165 - 6177, XP055586386
OPPOSITION- Artz Annette, Butz Stefan, Vestweber Dietmar, "GDF-15 inhibits integrin activation and mouse neutrophil recruitment through the ALK-5/TGF-βRII heterodimer", Blood, (20160728), vol. 128, no. 4, doi:10.1182/blood-2016-01-696617, ISSN 0006-4971, pages 529 - 541, XP093035275
OPPOSITION- Melero Bermejo Ignacio, De Miguel Maria J., Alonso Guzman, Ramelyte Egle, Joerger Markus, Sayehli Cyrus, Gromke Tanja, De Velasco Guillermo, Martin Liberal Juan, Garralda Elena, Rodriguez-Ruiz Maria E., Calvo Emiliano, Dummer Reinhard, Hess Dagmar, Goebeler Maria-Elisabeth, Schuler Martin H., Fettes Petra, Klar Kathrin, Hermann Frank, Leo Eugen, "Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).", Journal of Clinical Oncology, Grune & Stratton, (20230601), vol. 41, no. 16_suppl, doi:10.1200/JCO.2023.41.16_suppl.2501, ISSN 0732-183X, pages 2501 - 2501, XP093131806
OPPOSITION- Melero Ignacio, Et Al., "Neutralizing GDF-15 can overcome anti-PD-(L)1 resistance in late-stage cancer", Research Square, doi:10.21203/rs.3.rs-4003985/v1, (20240301), Research Square, URL: https://assets-eu.researchsquare.com/files/rs-4003985/v1_covered_5cb547ab-eef0-4972-b35e-138e43d24da7.pdf?c=1733990815, XP093259486
OPPOSITION- Jill Corre et al., "Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?", STEM CELLS TRANSLATIONAL MEDICINE , (2013), vol. 2, doi:10.5966/sctm.2013-0055, XP055330730

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents